A 24-Week Efficacy, Safety and Tolerability of Rivastigmine Patch Study in Patients With Probable Alzheimer's Disease
Status:
Completed
Trial end date:
2013-05-01
Target enrollment:
Participant gender:
Summary
The purpose of this study is to assess the efficacy, safety, and tolerability of Exelon®
patch in patients with probable AD (MMSE 10-20), in order to support a planned regulatory
submission and registration of Exelon transdermal patch in China. The study is designed to
confirm the non-inferiority of the efficacy of Exelon patch (target 10 cm² patch size) versus
Exelon capsules (target 6.0 mg bid dose) on cognition, using the Alzheimer's Disease
Assessment Scale-Cognitive Subscale (ADAS-Cog).